Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.043
Buy
RSI(14)
60.349
Neutral
STOCH(KDJ)(9,3,3)
70.847
Neutral
ATR(14)
0.163
Low Volatility
CCI(14)
136.409
Buy
Williams %R
34.426
Buy
TRIX(12,20)
1.129
Sell
StochRSI(14)
58.218
Sell
Search
PDS Biotechnology Corp
PDSBAdd to Watchlist
1.340USD
-0.090-6.29%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
74.79MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of PDS Biotechnology Corp
Currency: USD Updated: 2026-05-15Key Insights
PDS Biotechnology Corp's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 96 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
PDS Biotechnology Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
PDS Biotechnology Corp Highlights
StrengthsRisks
PDS Biotechnology Corporation is a clinical-stage immunotherapy company. The Company is developing a pipeline of targeted cancer immunotherapies based on its Versamune T cell-activator and Versamune in combination with its interleukin 12 (IL-12) fused antibody drug conjugate (ADC), PDS01ADC, a tumor targeting immunocytokine. PDS0101 is its lead Versamune based immunotherapy. PDS0101 combines Versamune with a mixture of short proteins (peptides) derived from the cancer-causing HPV16 viral protein. Versamune is a proprietary lipid nanoparticle and T cell activating platform. PDS0301 is an investigational tumor-targeting antibody conjugate of Interleukin 12 (IL-12) that enhances the proliferation, potency, infiltration, and longevity of T cells in the tumor microenvironment. Its Versamune immunotherapies and Versamune in combination with PDS01ADC, are utilized for treatments in oncology, and Infectimune is utilized for preventive vaccines against infectious agents.
Fairly Valued
The company’s latest PE is -2.01, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 9.62M shares, increasing 17.77% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 176.70K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.55.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.500
Target Price
+424.48%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Financial Health
Currency: USD Updated: 2026-05-15The current financial score of PDS Biotechnology Corp is 7.09, ranking 126 out of 382 in the Biotechnology & Medical Research industry. Its financial status is robust, and its operating efficiency is low.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.69
Operational Efficiency
4.00
Growth Potential
6.75
Shareholder Returns
7.03
PDS Biotechnology Corp's Company Valuation
Currency: USD Updated: 2026-05-15The current valuation score of PDS Biotechnology Corp is 7.55, ranking 97 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -2.01, which is -67.20% below the recent high of -0.66 and -317.53% above the recent low of -8.39.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 96/382
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2026-05-15The current earnings forecast score of PDS Biotechnology Corp is 8.00, ranking 161 out of 382 in the Biotechnology & Medical Research industry. The average price target is 4.50, with a high of 15.00 and a low of 3.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.500
Target Price
+424.48%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
554
Total
5
Median
6
Average
Company name
Ratings
Analysts
PDS Biotechnology Corp
PDSB
3
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
Beigene Ltd
ONC
26
Ionis Pharmaceuticals Inc
IONS
25
1
2
3
...
111
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2026-05-15The current price momentum score of PDS Biotechnology Corp is 8.62, ranking 52 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.64 and the support level at 0.95, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.300
Buy
MA10
1.201
Buy
MA20
1.134
Buy
MA50
0.922
Buy
MA100
0.867
Buy
MA200
0.941
Buy
Institutional Confidence
Currency: USD Updated: 2026-05-15The current institutional shareholding score of PDS Biotechnology Corp is 3.00, ranking 193 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 17.24%, representing a quarter-over-quarter increase of 61.48%. The largest institutional shareholder is James Simons, holding a total of 176.70K shares, representing 0.32% of shares outstanding, with 1.00% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Risk Assessment
Currency: USD Updated: 2026-05-15The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for PDS Biotechnology Corp. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 1.62. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. PDS Biotechnology Corp’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.
Score
Beta vs S&P 500 index
1.62
VaR
+8.27%
240-Day Maximum Drawdown
+70.03%
240-Day Volatility
+106.18%
Return
Best Daily Return
60 days
+28.30%
120 days
+28.30%
5 years
+28.30%
Worst Daily Return
60 days
-28.05%
120 days
-28.05%
5 years
-30.68%
Sharpe Ratio
60 days
+2.70
120 days
+1.61
5 years
-0.05
Risk Assessment
Maximum Drawdown
240 days
+70.03%
3 years
+91.86%
5 years
+96.86%
Return-to-Drawdown Ratio
240 days
-0.07
3 years
-0.27
5 years
-0.18
Skewness
240 days
+0.62
3 years
+0.47
5 years
+0.42
Volatility
Realised Volatility
240 days
+106.18%
5 years
+97.31%
Standardised True Range
240 days
+6.90%
5 years
+27.10%
Downside Risk-Adjusted Return
120 days
+262.71%
240 days
+262.71%
Maximum Daily Upside Volatility
60 days
+117.28%
Maximum Daily Downside Volatility
60 days
+86.32%
Liquidity
Average Turnover Rate
60 days
+1.75%
120 days
+1.59%
5 years
--
Turnover Deviation
20 days
+50.18%
60 days
+23.88%
120 days
+12.75%
Peer Comparison
Biotechnology & Medical Research
PDS Biotechnology Corp
PDSB
6.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
BioCryst Pharmaceuticals Inc
BCRX
8.57 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Ascendis Pharma A/S
ASND
8.48 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Exelixis Inc
EXEL
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alkermes Plc
ALKS
8.44 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
